BioVie Analyst Ratings
BioVie Analyst Ratings
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | → Outperform |
| 09/28/2022 | 58.1% | EF Hutton | $14 → $8 | Maintains | Buy |
| 07/22/2022 | 38.34% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 03/17/2022 | 176.68% | EF Hutton | $9 → $14 | Maintains | Buy |
| 03/15/2022 | 77.87% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 433.6% | B. Riley Securities | $50 → $27 | Maintains | Buy |
| 01/15/2021 | 828.85% | B. Riley Securities | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | 奧本海默 | → 十二美元 | 重申 | → 跑贏大市 |
| 09/28/2022 | 58.1% | EF 赫頓 | 十四美元 → 8 美元 | 維護 | 購買 |
| 2022 年 7 月 22 日 | 38.34% | 康托·菲茨杰拉德 | → 7 美元 | 啟動覆蓋範圍 | → 超重 |
| 03/17/2022 | 176.68% | EF 赫頓 | 九元 → 十四美元 | 維護 | 購買 |
| 03/15/2022 | 77.87% | 奧本海默 | → 9 美元 | 啟動覆蓋範圍 | → 跑贏大市 |
| 2021 年 11 月 30 日 | 433.6% | B. 萊利證券 | 五十元 → 二十七美元 | 維護 | 購買 |
| 01/15/2021 | 828.85% | B. 萊利證券 | → 四十七美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for BioVie (BIVI)?
生物維（BIVI）的目標價格是多少？
The latest price target for BioVie (NASDAQ: BIVI) was reported by Oppenheimer on February 14, 2023. The analyst firm set a price target for $12.00 expecting BIVI to rise to within 12 months (a possible 137.15% upside). 5 analyst firms have reported ratings in the last year.
奧本海默於 2023 年 2 月 14 日報導了 BioVie（納斯達克股票代碼：BIVI）的最新價格目標。該分析師公司設定了 12.00 美元的價格目標，預計 BIVI 將在 12 個月內上升（可能上漲 137.15％）。5 家分析師公司在去年報告了評級。
What is the most recent analyst rating for BioVie (BIVI)?
BioVie (BIVI) 的最新分析師評級為何？
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Oppenheimer, and BioVie reiterated their outperform rating.
BioVie（納斯達克股票代碼：BIVI）的最新分析師評級由奧本海默提供，BioVie 重申其表現突出的評級。
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
BioVie（BIVI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
分析師在進行了廣泛的研究後獲得了股票評級，其中包括通過公共財務報表，與 BioVie 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。BioVie 的最後一個評分於 2023 年 2 月 14 日提交，因此您應該預計下一個評分將在 2024 年 2 月 14 日左右的某個時候提供。
Is the Analyst Rating BioVie (BIVI) correct?
分析師評級生物維（BIVI）是否正確？
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.
儘管評分是主觀的並且會發生變化，但最新的 BioVie（BIVI）評級重申，目標價格為 0.00 美元至 12.00 美元。目前的價格 BioVie（BIVI）的交易價格為 5.06 美元，位於分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
